TY - JOUR
T1 - Replicative DNA polymerase defects in human cancers
T2 - Consequences, mechanisms, and implications for therapy
AU - Barbari, Stephanie R.
AU - Shcherbakova, Polina V.
N1 - Funding Information:
We thank Garrett Barbari for creative help in the preparation of Fig. 1 and Youri Pavlov for critically reading the manuscript. Research in the laboratory of P.V.S. was supported by the National Institutes of Health grant ES015869 and Nebraska Department of Health and Human Services LB506 grants. S.R.B. is supported by the Cancer Biology Training Grant T32CA009476 from the National Cancer Institute.
Publisher Copyright:
© 2017 Elsevier B.V.
PY - 2017/8
Y1 - 2017/8
N2 - The fidelity of DNA replication relies on three error avoidance mechanisms acting in series: nucleotide selectivity of replicative DNA polymerases, exonucleolytic proofreading, and post-replicative DNA mismatch repair (MMR). MMR defects are well known to be associated with increased cancer incidence. Due to advances in DNA sequencing technologies, the past several years have witnessed a long-predicted discovery of replicative DNA polymerase defects in sporadic and hereditary human cancers. The polymerase mutations preferentially affect conserved amino acid residues in the exonuclease domain and occur in tumors with an extremely high mutation load. Thus, a concept has formed that defective proofreading of replication errors triggers the development of these tumors. Recent studies of the most common DNA polymerase variants, however, suggested that their pathogenicity may be determined by functional alterations other than loss of proofreading. In this review, we summarize our current understanding of the consequences of DNA polymerase mutations in cancers and the mechanisms of their mutator effects. We also discuss likely explanations for a high recurrence of some but not other polymerase variants and new ideas for therapeutic interventions emerging from the mechanistic studies.
AB - The fidelity of DNA replication relies on three error avoidance mechanisms acting in series: nucleotide selectivity of replicative DNA polymerases, exonucleolytic proofreading, and post-replicative DNA mismatch repair (MMR). MMR defects are well known to be associated with increased cancer incidence. Due to advances in DNA sequencing technologies, the past several years have witnessed a long-predicted discovery of replicative DNA polymerase defects in sporadic and hereditary human cancers. The polymerase mutations preferentially affect conserved amino acid residues in the exonuclease domain and occur in tumors with an extremely high mutation load. Thus, a concept has formed that defective proofreading of replication errors triggers the development of these tumors. Recent studies of the most common DNA polymerase variants, however, suggested that their pathogenicity may be determined by functional alterations other than loss of proofreading. In this review, we summarize our current understanding of the consequences of DNA polymerase mutations in cancers and the mechanisms of their mutator effects. We also discuss likely explanations for a high recurrence of some but not other polymerase variants and new ideas for therapeutic interventions emerging from the mechanistic studies.
KW - Cancer
KW - DNA polymerase δ
KW - DNA polymerase ε
KW - Mutator
KW - Proofreading
UR - http://www.scopus.com/inward/record.url?scp=85021734323&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85021734323&partnerID=8YFLogxK
U2 - 10.1016/j.dnarep.2017.06.003
DO - 10.1016/j.dnarep.2017.06.003
M3 - Review article
C2 - 28687338
AN - SCOPUS:85021734323
SN - 1568-7864
VL - 56
SP - 16
EP - 25
JO - DNA Repair
JF - DNA Repair
ER -